ATE480630T1 - Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen - Google Patents

Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen

Info

Publication number
ATE480630T1
ATE480630T1 AT03740792T AT03740792T ATE480630T1 AT E480630 T1 ATE480630 T1 AT E480630T1 AT 03740792 T AT03740792 T AT 03740792T AT 03740792 T AT03740792 T AT 03740792T AT E480630 T1 ATE480630 T1 AT E480630T1
Authority
AT
Austria
Prior art keywords
viral particles
binding activity
cell binding
altered cell
producing viral
Prior art date
Application number
AT03740792T
Other languages
English (en)
Inventor
Colin Casimir
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of ATE480630T1 publication Critical patent/ATE480630T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03740792T 2002-07-11 2003-07-11 Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen ATE480630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216081.0A GB0216081D0 (en) 2002-07-11 2002-07-11 Methods of making biological materials and uses thereof
PCT/GB2003/003012 WO2004007735A1 (en) 2002-07-11 2003-07-11 Methods of making viral particles having a modified cell binding activity and uses thereof

Publications (1)

Publication Number Publication Date
ATE480630T1 true ATE480630T1 (de) 2010-09-15

Family

ID=9940253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740792T ATE480630T1 (de) 2002-07-11 2003-07-11 Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen

Country Status (9)

Country Link
US (2) US20060110361A1 (de)
EP (1) EP1521839B8 (de)
JP (1) JP4509780B2 (de)
AT (1) ATE480630T1 (de)
AU (1) AU2003281072B2 (de)
CA (1) CA2494245A1 (de)
DE (1) DE60334097D1 (de)
GB (1) GB0216081D0 (de)
WO (1) WO2004007735A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1791565T3 (pl) * 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
WO2007061141A1 (ja) 2005-11-24 2007-05-31 Genomidea, Inc. 改変パラミクソウイルスおよびその作製方法
US7674240B2 (en) 2005-12-20 2010-03-09 Abbott Cardiovascular Systems Inc. Method and apparatus for controlled vessel occlusion
GB201105584D0 (en) 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
US9522257B2 (en) 2012-03-30 2016-12-20 Abbott Cardiovascular Systems Inc. Integrated controlled volume inflator device, components, and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
GB9519776D0 (en) * 1995-09-28 1995-11-29 Casimir Colin Materials and methods relating to the transfer of nucleic acid into stem cells
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
WO2002048329A2 (en) * 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor

Also Published As

Publication number Publication date
JP2005532075A (ja) 2005-10-27
EP1521839B1 (de) 2010-09-08
EP1521839A1 (de) 2005-04-13
CA2494245A1 (en) 2004-01-22
EP1521839B8 (de) 2010-11-10
AU2003281072A1 (en) 2004-02-02
AU2003281072B2 (en) 2008-04-03
JP4509780B2 (ja) 2010-07-21
US20060110361A1 (en) 2006-05-25
US20110020901A1 (en) 2011-01-27
GB0216081D0 (en) 2002-08-21
DE60334097D1 (de) 2010-10-21
WO2004007735A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DE60326927D1 (de) Verwendung von p38/JTV-1 zur Behandlung von Krebs
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
HK1125674A1 (en) Rescue of influenza virus
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
ATE418346T1 (de) Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
ATE199828T1 (de) Verfahren zur konditionierung von substanzen
WO2005003296A3 (en) Albumin fusion proteins
DE69738791D1 (de) Methode zur behandlung von biopolymeren, mikroorganismen oder anderen materialien, die mehr als einen typ von magnetischen partikeln benutzt.
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2003047617A3 (en) Vaccine
DE602004018788D1 (de) Faktor-ixa-spezifische antikörper, die faktor-viiia-ähnliche wirkung zeigen
DE102005055128A1 (de) Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ATE504208T1 (de) Dekontaminationslösungen und deren verwendung zur denaturierung, modifikation, degradation, solubilisierung und entfernung von proteinen, nukleinsäuremolekülen und mikroorganismen
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
ATE480630T1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen
ATE334670T1 (de) Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen
ATE328102T1 (de) Verfahren zur herstellung von proteine
DE60334008D1 (de) Reduzierter slam abhängiger zell eintritt
MXPA04003969A (es) Sistema de expresion de acido nucleico regulado.
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
AU6111294A (en) Composition for use in the treatment of tumours and the immunization of humans and animals
DE60128950D1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties